Score Overview
PeriodNet IncomeRevenueScoreGrowthTrendConsistencyGrowthTrendConsistency
5 Years
5.8
72.03%
Every year
—
-103.68%
20%
—
5 Years
Score5.8
Net Growth72.03%
Net TrendEvery year
Net Income Consistency—
Rev Growth-103.68%
Rev Trend20%
Revenue Consistency—
Inovio Pharmaceuticals Inc fundamental performance
Between 2020 and 2025, revenue declined from $ 7M to $ 65.34K and net income went from -$ 166M to -$ 84M. Revenue increased in 1 of those 5 years; net income in every one.
Between 2015 and 2025, revenue declined from $ 40M to $ 65.34K and net income went from -$ 29M to -$ 84M. Revenue increased in 3 of those 10 years; net income in 5.
Inovio Pharmaceuticals Inc currently holds a 20-year HDB Score of 2.1 out of 10. How the HDB Score is calculated.
Net Income x Stock Price
Historical Returns
| Period | Price | Return |
|---|---|---|
Last Price2026-08-12 | $ 0.77 | — |
1 Year2025-08-12 | $ 1.49 | -48.32% |
5 Years2021-08-12 | $ 116.28 | -99.34% |
10 Years2016-08-12 | $ 107.02 | -99.28% |
20 Years2006-08-11 | $ 112.87 | -99.32% |
| Period | Last Price2026-08-12 | 1 Year2025-08-12 | 5 Years2021-08-12 | 10 Years2016-08-12 | 20 Years2006-08-11 |
|---|---|---|---|---|---|
| Price | $ 0.77 | $ 1.49 | $ 116.28 | $ 107.02 | $ 112.87 |
| Return | — | -48.32% | -99.34% | -99.28% | -99.32% |
Prices are split & dividend adjusted. All values are reported in USD.
Fundamental Data
| Year | |||
|---|---|---|---|
| 2026 | -$ 65.34K | -$ 84M | $ 37M |
| 2025 | $ 65.34K | -$ 84M | $ 58M |
| 2024 | $ 217.76K | -$ 107M | $ 94M |
| 2023 | $ 832.01K | -$ 135M | $ 145M |
| 2022 | $ 10M | -$ 279M | $ 252M |
| 2021 | $ 1M | -$ 303M | $ 401M |
| 2020 | $ 7M | -$ 166M | $ 411M |
| 2019 | $ 4M | -$ 119M | $ 89M |
| 2018 | $ 30M | -$ 96M | $ 81M |
| 2017 | $ 42M | -$ 88M | $ 127M |
| 2016 | $ 35M | -$ 73M | $ 104M |
| 2015 | $ 40M | -$ 29M | $ 162M |
| 2014 | $ 10M | -$ 36M | $ 93M |
| 2013 | $ 13M | -$ 66M | $ 52M |
| 2012 | $ 4M | -$ 19M | $ 13M |
| 2011 | $ 9M | -$ 15M | $ 30M |
| 2010 | $ 6M | -$ 17M | $ 21M |
| 2009 | $ 9M | -$ 24M | $ 43M |
| 2008 | $ 2M | -$ 12M | $ 14M |
| 2007 | $ 4M | -$ 11M | $ 27M |
| 2006 | $ 3M | -$ 12M | $ 23M |
| 2005 | $ 5M | -$ 15M | $ 17M |
| 2004 | $ 1M | -$ 10M | $ 17M |
| 2003 | $ 80.53K | -$ 4M | $ 13M |
| 2002 | $ 189.52K | -$ 5M | $ 875.44K |
| 2001 | $ 4M | -$ 8M | $ 1M |
| 2000 | $ 5M | -$ 9M | $ 6M |
| 1999 | $ 8M | -$ 6M | $ 9M |
| IPO1998 | $ 8M | -$ 6M | $ 6M |
Explore beyond INO
You're looking at Inovio Pharmaceuticals Inc. Members apply the same fundamental framework across all 3,860 companies we cover.
- Every HDB Score — 1, 5, 10, 20 and 30 years, plus all-time
- Revenue and Net Income Consistency for every period
- Rank all 3,860 companies by any metric, not just three
- Filter by sector and currency, and page through the whole list
- Track your holdings in a portfolio
$99/year $149 founding price
Unlock Holder Dashboard30-day money-back guarantee.
